CHGCY (Chugai Pharmaceutical Co) Dividend Payout Ratio : 0.67 (As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Chugai Pharmaceutical Co's Dividend Payout Ratio for the months ended in Jun. 2024 was 0.67.

The historical rank and industry rank for Chugai Pharmaceutical Co's Dividend Payout Ratio or its related term are showing as below:

CHGCY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.31 Med: 0.41 Max: 0.53
Current: 0.35

During the past 13 years, the highest Dividend Payout Ratio of Chugai Pharmaceutical Co was 0.53. The lowest was 0.31. And the median was 0.41.

CHGCY's Dividend Payout Ratio is ranked better than
55.38% of 437 companies
in the Drug Manufacturers industry
Industry Median: 0.37 vs CHGCY: 0.35

As of today (2024-12-13), the Dividend Yield % of Chugai Pharmaceutical Co is 1.27%.

During the past 13 years, the highest Trailing Annual Dividend Yield of Chugai Pharmaceutical Co was 2.51%. The lowest was 0.55%. And the median was 1.27%.

Chugai Pharmaceutical Co's Dividends per Share for the months ended in Jun. 2024 was $0.14.

During the past 12 months, Chugai Pharmaceutical Co's average Dividends Per Share Growth Rate was 1.30% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 17.00% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 29.70% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 21.80% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Chugai Pharmaceutical Co was 46.80% per year. The lowest was 4.00% per year. And the median was 11.50% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Chugai Pharmaceutical Co Dividend Payout Ratio Historical Data

The historical data trend for Chugai Pharmaceutical Co's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Dividend Payout Ratio Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

0.47

0.40

0.39

0.40

0.39

Chugai Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	0.67	-	0.67	-

Competitive Comparison of Chugai Pharmaceutical Co's Dividend Payout Ratio

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Dividend Payout Ratio falls into.

Chugai Pharmaceutical Co Dividend Payout Ratio Calculation

Chugai Pharmaceutical Co's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0.267	/	0.687
	=	0.39

Chugai Pharmaceutical Co's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0.144	/	0.215
	=	0.67

Chugai Pharmaceutical Co (OTCPK:CHGCY) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Chugai Pharmaceutical Co Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

CHGCF:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.